Compare LULU & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LULU | INCY |
|---|---|---|
| Founded | 1998 | 1991 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9B | 17.0B |
| IPO Year | 2007 | 1994 |
| Metric | LULU | INCY |
|---|---|---|
| Price | $173.43 | $98.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 25 | 21 |
| Target Price | ★ $212.97 | $100.63 |
| AVG Volume (30 Days) | ★ 1.9M | 1.7M |
| Earning Date | 03-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.00 | ★ 4173.33 |
| EPS | ★ 8.29 | 6.41 |
| Revenue | ★ $10,588,126,000.00 | $3,394,635,000.00 |
| Revenue This Year | $6.59 | $11.02 |
| Revenue Next Year | $4.40 | $9.97 |
| P/E Ratio | $21.05 | ★ $15.28 |
| Revenue Growth | 10.07 | ★ 13.67 |
| 52 Week Low | $159.25 | $53.56 |
| 52 Week High | $363.88 | $112.29 |
| Indicator | LULU | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 43.63 |
| Support Level | $160.62 | $82.66 |
| Resistance Level | $184.31 | $108.79 |
| Average True Range (ATR) | 6.32 | 2.89 |
| MACD | 0.21 | -0.30 |
| Stochastic Oscillator | 21.33 | 28.49 |
Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. The company offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. Lululemon also sells fitness accessories, such as bags, yoga mats, and equipment. It sells its products through digital channels, a small number of wholesale partners, more than 780 company-owned stores in about two dozen countries in North America, Asia, and Western Europe, and about 40 franchised locations in the Middle East and Europe. The company was founded in 1998 and is based in Vancouver, Canada.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.